Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
CEPHEUS
1 other identifier
observational
8,000
8 countries
59
Brief Summary
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2008
Shorter than P25 for all trials
59 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2008
CompletedFirst Submitted
Initial submission to the registry
May 28, 2008
CompletedFirst Posted
Study publicly available on registry
May 30, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2008
CompletedDecember 2, 2010
December 1, 2010
7 months
May 28, 2008
December 1, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP â…¢ guidelines(overall and by country)
After collecting all Patient Record Form.
Secondary Outcomes (3)
The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP â…¢ guidelines for several subject subsets.
After collecting all Patient Record Form.
The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPâ…¢ guidelines and patient and physician variables.
After collecting all Patient Record Form.
The physician characteristics associated with the allocation of hypercholesterolemia treatment regime.
After collecting all Patient Record Form.
Eligibility Criteria
Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
You may qualify if:
- or more risk factors (according to NCEP ATP III guideline)
- Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.
You may not qualify if:
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
- Previous enrolment or randomisation of treatment in the present study.
- Participation in a clinical study during the last 90 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (59)
Research Site
Hong Kong, Hong Kong, China
Research Site
Semarang, Central Java, Indonesia
Research Site
Jakarta, DKI Jakarta, Indonesia
Research Site
Sidoarjo, East Java, Indonesia
Research Site
Surabaya, East Java, Indonesia
Research Site
Medan, North Sumatra, Indonesia
Research Site
Bandung, West Java, Indonesia
Research Site
Bangsar, Kuala Lumpur, Malaysia
Research Site
Kepong, Kuala Lumpur, Malaysia
Research Site
Kuala Lumpur, Kuala Lumpur, Malaysia
Research Site
Puchong, Kuala Lumpur, Malaysia
Research Site
Setapak, Kuala Lumpur, Malaysia
Research Site
Ampang, Selangor, Malaysia
Research Site
Batu Caves, Selangor, Malaysia
Research Site
Hulu Selangor, Selangor, Malaysia
Research Site
Kampung Baru Subang, Selangor, Malaysia
Research Site
Klang, Selangor, Malaysia
Research Site
Kuala Selangor, Selangor, Malaysia
Research Site
Petaling Jaya, Selangor, Malaysia
Research Site
Port Klang, Selangor, Malaysia
Research Site
Sekinchan, Selangor, Malaysia
Research Site
Seri Kembangan, Selangor, Malaysia
Research Site
Shah Alam, Selangor, Malaysia
Research Site
Subang Jaya, Selangor, Malaysia
Research Site
Sungai Buloh, Selangor, Malaysia
Research Site
Sunway City, Selangor, Malaysia
Research Site
Lipa, Batangas, Philippines
Research Site
Baguio City, Benguet, Philippines
Research Site
Davao City, Davao Region, Philippines
Research Site
Iloilo City, Iloilo, Philippines
Research Site
Manila, Manila, Philippines
Research Site
Cheonan, Chung-Cheong-nam-do, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Bundang, Gyeonggi-do, South Korea
Research Site
Guri-si, Gyeonggi-do, South Korea
Research Site
Il-san, Gyeonggi-do, South Korea
Research Site
Suwon, Gyeonggi-do, South Korea
Research Site
Masan, Gyung-sang-nam-do, South Korea
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Gwangju, South Korea
Research Site
Incheon, South Korea
Research Site
Jeju City, South Korea
Research Site
Seoul, South Korea
Research Site
Ulsan, South Korea
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, Taiwan
Research Site
Bangkoknoi, Bangkok, Thailand
Research Site
Dusit, Bangkok, Thailand
Research Site
Pathumwan, Bangkok, Thailand
Research Site
Ratchathewi, Bangkok, Thailand
Research Site
Klongluang, Changwat Pathum Thani, Thailand
Research Site
Muang, ChiangMai, Thailand
Research Site
Hanoi, Hanoi, Vietnam
Research Site
Ho Chi Minh City, Hcmc, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Park Jeong Euy
Sungkyunkwan University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 28, 2008
First Posted
May 30, 2008
Study Start
May 1, 2008
Primary Completion
December 1, 2008
Study Completion
December 1, 2008
Last Updated
December 2, 2010
Record last verified: 2010-12